Krystal Biotech, Inc. reported significant financial growth in its latest quarterly results, with product revenue reaching $97.8 million for the three months ended September 30, 2025, a 17% increase from $83.8 million in the same period last year. For the nine months ending September 30, 2025, total product revenue was $282 million, up 41% from $199.4 million in the prior year. The company achieved a net income of $79.4 million for the third quarter, compared to $27.2 million in the same quarter of 2024, marking a 192% increase. This surge in profitability was attributed to increased sales of its gene therapy product, VYJUVEK, which has been pivotal in driving revenue growth.
The company also reported a decrease in total operating expenses, which fell to $56.4 million in Q3 2025 from $61.4 million in Q3 2024, primarily due to a reduction in the cost of goods sold, which decreased by 36% to $4.3 million. This reduction was a result of manufacturing optimizations that lowered average costs per unit. Research and development expenses rose by 8% to $14.6 million, reflecting ongoing investments in product development, while selling, general, and administrative expenses increased by 31% to $37.6 million, driven by higher professional services and marketing costs.
In terms of operational metrics, Krystal Biotech's cash and cash equivalents increased to $392.6 million as of September 30, 2025, up from $344.9 million at the end of 2024. The company also reported an accumulated deficit of $27.2 million, a significant improvement from $180.7 million at the end of the previous fiscal year. The total assets of the company rose to $1.24 billion, compared to $1.06 billion at the end of 2024, indicating a strong balance sheet bolstered by increased cash reserves and investments.
Strategically, Krystal Biotech has made significant strides in expanding its market presence. The company launched VYJUVEK in Germany in August 2025 and in France in October 2025, following approvals in the U.S., Europe, and Japan. The product is now available for patients from birth, with flexible dosing options. The company is also preparing for regulatory filings in the UK and Switzerland, and has established distribution agreements with specialty distributors in various regions. These developments are expected to enhance the company's market share and product adoption rates in the coming quarters.
Looking ahead, Krystal Biotech anticipates continued revenue growth driven by the commercialization of VYJUVEK and the advancement of its product pipeline. The company plans to leverage its cash reserves and revenue from VYJUVEK to fund ongoing operations and may seek additional capital through strategic partnerships or financing arrangements. Management remains optimistic about the future, citing the potential for further product approvals and market expansions as key drivers of growth.
About Krystal Biotech, Inc.
Krystal Biotech is a biotechnology company specializing in gene therapies for rare and serious diseases. Using its proprietary HSV-1 platform, it develops and commercializes treatments like VYJUVEK for dystrophic epidermolysis bullosa and pipeline candidates for ophthalmology, respiratory, oncology, and dermatology. The company focuses on non-invasive, repeatable gene delivery to address high unmet medical needs globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.